DotBio focuses on the development of multi-functional antibodies with synergistic activities to cure cancer. DotBio's approach involves the use of its modular DotBody technology platform, high-throughput miniaturized assays and pattern-recognition algorithms to generate molecules with unique modes of action. DotBio secured USD 2.3 M in Seed funding in 2018, and is now raising USD 20 M in Series A to bring its capabilities to the next level: increase throughput, improve data analytics capabilities and bring three molecules towards the clinic through partnerships.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):